Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × ispinesib × Breast × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3 Lymphoid 2 Genitourinary 2 Gastrointestinal 2 Thoracic 1 Sarcoma 1 Other hematologic neoplasm 1 Head & Neck 1 Gynecologic 1 Dermatologic 1 Classical hematology 1 CNS 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 342 Paclitaxel 331 Cyclophosphamide 300 Docetaxel 279 Capecitabine 184 Doxorubicin 174 Letrozole 167 Tamoxifen 142 Carboplatin 131 Fulvestrant 121 Bevacizumab 114 Lapatinib 111 Anastrozole 109 exemestane 108 Gemcitabine 103 Epirubicin 99 Radiotherapy 98 palbociclib 80 Vinorelbine 74 Surveys and Questionnaires 73 Exercise 73 Fluorouracil 72 Albumin-Bound Paclitaxel 68 pertuzumab 66 Filgrastim 62 Magnetic Resonance Spectroscopy 57 130-nm albumin-bound paclitaxel 57 Everolimus 56 eribulin 55 Cisplatin 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00089973 2018-02-26

Study Of Ispinesib In Subjects With Breast Cancer

GlaxoSmithKline

Phase 2 Completed

50 enrolled 12 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡